T-R:T(Regorafenib 40mg) for the first period and R(Stivarga 40mg) for the second period
Sponsors
Beijing shijitan hospital affiliated to capital medical university
Conditions
mCRC/GIST/HCCmetastatic colorectal cancer (mCRC), gastrointestinal stromal tumor (GIST), hepatocellular carcinoma (HCC)
Phase 1
Randomized, open, single-dose, two-period, cross-over bioequivalence study of regorafenib in healthy volunteers under fasting condition
Active, not recruitingChiCTR2400092562
Start: 2021-09-22Updated: 2024-12-02
Randomized, open, single-dose, two-period, cross-over bioequivalence study of regorafenib in healthy volunteers under low-fat fed condition
Active, not recruitingChiCTR2400093332
Start: 2021-06-16Updated: 2024-12-09